The pharma services and drug developer Ergomed Plc (LON:ERGO) has appointed a new chief executive.
He is Dr Dan Weng, who joins on July 1 from EPS Holdings, a Tokyo-listed contract research business.
He will take the reins from the company’s founder, Dr Miroslav Reljanovic, who will become executive vice-chairman.
“I'm very pleased to welcome Dan to the team to guide Ergomed forward as we seek to build on the strong growth of our CRO [contract research] and pharmacovigilance businesses,” said Reljanovic.
“I look forward to contributing to Ergomed's continued success as vice-chairman, focusing on our existing and future co-development deals, our pipeline products, and the broader strategy of the business."